Subcutaneous Implantable-Defibrillator is Better to Be a “collaborator” Rather Than a “Replacement”

Tao Tu,Qiming Liu,Shenghua Zhou

DOI: https://doi.org/10.1016/j.ijcard.2014.09.072

IF: 4.039

2014-01-01

International Journal of Cardiology

Abstract:In order to avoid intravascular lead complications, the totally subcutaneous implantable-defibrillator (S-ICD) has been developed to replace the conventional transvenous ICD system (T-ICD). This novel device, developed and tested over the past decade, gained approval as accepted therapy for detection and termination of ventricular arrhythmias. The advantages of this nontransvenous ICD system are obvious, including elimination of complications related to venous access, no physical stress on leads associated with cardiac motion, less morbidity associated with device extraction and a potential reduction in endovascular infection risk [ [1] Poole J.E. Gold M.R. Who should receive the subcutaneous implanted defibrillator?: the subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013; 6: 1236-1244 Crossref PubMed Scopus (36) Google Scholar ]. People optimistically proposed that S-ICD may replace T-ICD and should be considered for all patients without pacing needs undergoing ICD implantation [ [1] Poole J.E. Gold M.R. Who should receive the subcutaneous implanted defibrillator?: the subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013; 6: 1236-1244 Crossref PubMed Scopus (36) Google Scholar ]. However, in addition to the redeeming virtues, the evident limitations of S-ICD should not be neglected.